Navigation Links
Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges
Date:2/3/2013

Kiev, Ukraine (PRWEB) February 02, 2013

Ekomed company is pleased to announce that Immunoxel formulated into Honey Lozenges™ has been awarded Global Science & Technology Entrepreneurship Program (STEP) grant from the Civilian Research & Development Foundation (CRDF). CRDF is the non-profit organization authorized by the US Congress and established in 1995 by the National Science Foundation. STEP is funded by the US Department of State and in part by the State Agency of Ukraine for Science, Innovation, and Information. The grant will support clinical trial and joint marketing initiative of honey-formulated herbal supplement, Immunoxel, shown clinically effective as an immune adjunct against tuberculosis.

TB is a global killer. According to the WHO two billion people or 1/3 of the global population is latently infected with Mycobacterium tuberculosis. Annually, nearly 9 million of these people develop active TB and 2 million die. Current tuberculosis drugs are 50 years old, not very effective, must be taken for 6-9 months for drug-sensitive TB and up to 36 months for drug-resistant strains - MDR-TB and XDR-TB. Thus, new alternative approaches are urgently needed. One of them is immunotherapy, which is believed to enhance the efficacy of chemotherapy and shorten treatment duration.

The proprietary water-alcohol phytoconcentrate of 25 herbs, Immunoxel (Dzherelo), was developed by Ukrainian company Ekomed in 1997. This herbal tincture is widely available in Ukrainian pharmacies and has been used as an immune supplement to treat various infectious diseases such as seasonal flu, TB and HIV. Published studies spanning over the past 15 years count nearly twenty clinical trials involving more than 1,500 TB and AIDS patients. These studies have demonstrated that herbal extract taken along with conventional drugs can clear bacteria in 2-4 months instead of usual 6-24 months. While these results are clearly in favor of Immunoxel, they are not ideal, since the duration of therapy is not optimal and faster-acting regimens are still needed. In order to overcome this drawback four types of solid, sublingual formulations of Immunoxel were made and tested clinically to see if they performed better.

The most optimal delivery vehicle was Honibe honey lozenge currently sold for sore throat and nasal congestion relief. The new version of Immunoxel was developed jointly by two Canadian companies, Island Abbey Foods Ltd., and Immunitor Inc. The project was funded by earlier-issued CRDF grant which was successfully completed last year. The outcome of the clinical trial was published in Immunotherapy – a peer-reviewed journal from Future Medicine – a science publisher based in London, UK.

“It is a great honor for me personally and for our Canadian and Ukrainian partners to be among winners of the STEP grant” stated John Rowe, President of Island Abbey Foods Ltd. “We are very proud to be able to contribute to the global fight against TB”. Dr. Allen Bain, Director of Immunitor Inc, another company based in Charlottetown, PEI, and co-recipient of the grant added: "This success will help boost our fundraising efforts for expanded multinational trials and marketing in high TB burden countries in Africa and Asia. The ultimate Idea to Market goal endorsed by CRDF is thus fulfilled".

The anti-mycobacterial activity of honey has been known since ancient times and it is used as a folk medicine even today. Several in vitro studies demonstrated the direct inhibition of tubercle bacilli growth by honey. There are also published clinical studies showing its benefit in healing tuberculous lesions and counteracting the toxicity of TB drugs. “Remarkable anti-TB activity resulted from once-daily dose of herbal honey lozenge. It is likely that the combination of Immunoxel with honey produced synergistic effect observed in our trial. The goal of the future study, to be funded by CRDF, is to confirm our preliminary findings, so that we have an easy-to-administer tableted form of TB immunotherapy,” concluded Volodymyr Pylypchuk, Director General of Kiev-based Ekomed.

Media Inquiries:
Ekomed LLC.
Volodymyr Pylypchuk
Email: pylypchuk(at)bk(dot)ru

Read the full story at http://www.prweb.com/releases/2013/2/prweb10382670.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vaccination reduces the risk of unvaccinated badger cubs testing tuberculosis positive
2. From the mouths of monkeys: Swab technique spots tuberculosis in non-human primates
3. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant
4. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
5. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
6. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. OsteoVantage™ Receives Grant from the National Science Foundation
9. Boyd Coatings Awarded Workforce Training Grant
10. Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical Ltd. to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
11. University of Minnesota awarded $28 million grant to lead microelectronics development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...  With the growing need for better therapeutics, ... therapies such as monoclonal antibodies, recombinant protein therapeutics ... indications are in high demand. Conventionally expression systems ... production of these therapeutics. However, due to issues ... novel approaches and novel expression systems are currently ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... a new office dedicated to the North American healthcare market. , Aerocom Healthcare, ... healthcare facilities. The company will provide new pneumatic tube systems or expand ...
(Date:2/3/2016)... CA (PRWEB) , ... February 03, 2016 , ... ... of remote Linux and Unix visualization solutions today announced the addition of a ... Preview allows users to see the current state of the remote Linux desktop ...
Breaking Biology Technology:
(Date:1/11/2016)... 2016  higi, the leading retail and omni-channel community ... web and mobile, today announced it has closed ... investors. --> --> ... innovate higi,s health platform – its network of ... including expanding services and programs to retail partners ...
(Date:1/8/2016)... OXFORD, Connecticut , January 8, 2016 ... growing m-commerce market and WorldVentures ® , a privately ... memberships and an Inc. 5000 fastest-growing company ... a strategic investment of $2 million in Nxt-ID to ... members based on Nxt-ID,s Wocket ® , a unique ...
(Date:1/7/2016)... , Jan. 7, 2016 Various factors ... biopharmaceutical products such as biologics and biosimilars. Some ... reduce healthcare expenditure, growing demand for cost-effective alternatives, ... population. Biosimilars are similar versions of their corresponding ... to their quality, safety, and efficacy. The global ...
Breaking Biology News(10 mins):